Skip to main content
Toggle Menu

About

Novatia, LLC is a US-based research organization with offices and laboratories located just North of Philadelphia in Newtown, PA.  We provide products and services to clients in the chemical, pharmaceutical and life science industries using our expertise in instrumentation, automation, software development, and analytical & synthetic chemistry.

Novatia specializes in qualitative analysis for structure determination using Nuclear Magnetic Resonance (NMR), Liquid Chromatography (LC) and Mass Spectrometry (MS).   In addition to routine analysis of samples by MS and NMR, Novatia regularly provides component isolation & identification services, which leverages our analytical, synthetic chemistry and pharmaceutical expertise to solve problems in small molecule drug development.  Our knowledge and experience with the international regulatory landscape also enables us to help clients troubleshoot a wide scope of biopharmaceutical problems from early development to manufacturing.

Novatia’s proprietary ProMass software allows for completely automated biomolecule charge deconvolution and web-based reporting of electrospray ionization mass spectral data.  ProMass is available for both Waters MassLynx and Thermo Scientific Xcalibur platforms.  Our Oligo HTCS platform, which uses ProMass as the data processing and reporting engine, is a turnkey LC/MS system designed to automate every aspect of oligonucleotide mass spectral analysis. Oligo HTCS is available for installation in any laboratory to characterize oligonucleotides using either high-throughput or detailed LC/MS protocols. This software-instrumentation combination has allowed users of over 40 systems worldwide to generate high-quality, automated data for countless oligonucleotides over the past 15 years.

Novatia utilizes our ProMass and Oligo HTCS technology to analyze client samples in our own laboratories.  We also provide an array of characterization services using both NMR and MS on biomolecules such as oligonucleotides, monoclonal antibodies, and other protein therapeutics including biosimilars.